Association between interleukin 10 polymorphisms (-592C/A and - 819 C/T) with response to treatment in Iranian patients with hepatitis C virus

How to Cite:Farahnaz BineshianSanam MohseninZohreh SharifiAssociation between interleukin 10 polymorphisms (-592C/A and - 819 C/T) with response to treatment in Iranian patients with hepatitis C virus.20(3):e152984.

Abstract

Introduction: Interleukin-10 gene is an important gene for the hepatitis C virus (HCV) infection. Polymorphism in the promoter of interleukin 10 (IL-10) may influence the level of interleukin-10 production and also the susceptibility to inflammatory diseases. Therefore, the aim of this study was to determine the association between the polymorphism of -592C/A and -819 C/T - IL-10 with response to treatment in Iranian patients with HCV. Materials and Methods: In this study, 40 patients with HCV (response to treatment), 40 patients unresponsive to treatment and 40 healthy individuals were randomly selected. Genomic DNA was extracted from Buffy coat layer using salting out method.The genotype of -819 (C/T) IL-10 and -592 (C/A) IL-10 were determined by ARMS-PCR. PCR products were electrophoresis on agarose gel 1.2%. Levels of both aspartate aminotransferase (AST) and alanine aminotransferase) ALT (enzyme were determined. Results: The -592C/A - IL-10 genotype in the group that had respond to the treatment was more than other groups (without response to treatment) and also they were significantly associated with normal levels of AST (24.6 ± 8.5 IU / L) and ALT (28.3 ± 11.7 IU / L) (P = 0.01). Significant differences between groups regarding with polymorphism 819 C/T - IL-10 were not observed. Genotype 819 (T/T) - IL-10 was significantly more (P = 0.02) in the control group and in the group showed respons to treatment with normal levels of AST and ALT. Conclusion: Most patients with genotype -592C/A - IL-10- had a sustained viral response to treatment. However, further studies are needed to explore in more detail the response to treatment in the patients with -592C/A - IL-10 genotype.

Keywords

IL-10

Single Nucleotide Polymorphism

پلی‌مورفیسم تک نوکلئوتیدی

ویروس هپاتیتC

C/A 592-

C/T819-

References

1.
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015; 385: 1124-1135.
2.
Gower E, Estes C, Blach S, Razavi-Shearer K1, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-57.
3.
Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294-S302.
4.
Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
5.
Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 2013; 61: 478-484.
6.
Ramos JA, Silva R, Hoffmann L,Ramos AL, Cabello PH, Urmnyi TP, et al. Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes 2012; 5: 508.
7.
Commins S, Strinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. Allergy ClinImmunol 2008; 11_121: 1108.
8.
Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007; 85: 24-32.
9.
Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362-369.
10.
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
11.
Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526.
12.
Yilmaz V, Yentur SP, Saruhan-Dire-skeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005; 30: 188-194.
13.
Jalali S, Sharifi Z, Sanati MH, Fazeli AS. Survey on CCR5-32 mutation in healthy individuals and patients with chronic hepatitis B referred to the clinical laboratory of Iranian blood transfusion organization. Koomesh 2014; 15: 359-364.
14.
Hosseini A, Sharifi Z, Baghbani-Arani F. Survey on the association of CCR5 promoter -59353T/C polymorphism with HCV infection. J MazandaranUniv Med Sci 2014; 24: 45-53. (Persian).
15.
Bagheri MM, Sharifi Z, Sanati MH, Shahzadeh FA, Farhangnia M. The survey on-592 polymorphism of interlukin-10 in hepatitis b virus infected patients. J Isfahan Med School 2014; 31:1-8.(Persian).
16.
Rezaie M, khaleghian A. Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan province (Iran) from 2011 to 2015. Koomesh 2016; 17: 501-508.
17.
Attaran MS, Sharifi Z, Hosseini S M, Samei S , Ataee Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. APMIS 2014; 122:243-247. (Persian).
18.
Afzal MS, Tahir S, Salman A,Baig TA, Shafi T, Zaidi NU, Qadri I. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 2011; 5: 473-479.
19.
Chen TY, Hsech YS, Wu TT,Yang SF, Wu CJ, Tsay GJ, Chiou HL. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007; 150: 116-121.
20.
Chuang JY, Yang SS, Lu YT, Hsieh YY, Chen CY, Chang SC, et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009; 41: 424-430.
21.
Zhang LZ, Zhang TC, Pan FM, Zhang ZH, Li X. Interleukin-10 gene polymorphisms in association with susceptibility to chronic hepatitis C virus infection: a meta-analysis study. Arch Virol 2010; 155: 1839-1842.
22.
Gao QJ, Liu DW, Zhang SY,Jia M, Wang LM, Wu LH, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009; 15: 5610-5619.
23.
Sun XR, Wu J, Shi KQ, Tang KF. Relationship between IL-10 gene -1082A/G and -592C/A polymorphisms and the risk of hepatitis C infection: a meta-analysis. J Viral Hepat 2013; 20: 602-611.##.

comments